阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘后交易 12-26 17:23:21 EST

92.90

+0.45

+0.49%

盘后92.90

+0.000.00%

17:19 EST

最高92.91	最低92.18	成交量166.52万
今开92.53	昨收92.45	日振幅0.79%
总市值2,881亿	流通市值2,869亿	总股本31.01亿
成交额1.54亿	换手率0.05%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":92.9,"timestamp":1766782800000,"preClose":92.45,"halted":0,"volume":1665153,"hourTrading":{"tag":"盘后","latestPrice":92.9,"preClose":92.9,"latestTime":"17:19 EST","volume":67047,"amount":6228610.65099,"timestamp":1766787557755},"delay":0,"floatShares":3088302520,"shares":3101451738,"eps":3.009339,"marketStatus":"盘后交易","change":0.45,"latestTime":"12-26 17:23:21 EST","open":92.525,"high":92.91,"low":92.18,"amount":154351432.26688498,"amplitude":0.007896,"askPrice":93,"askSize":30,"bidPrice":92.41,"bidSize":1,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766797200000},"marketStatusCode":4,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":92.45,"dividendRate":0.016851,"preHourTrading":{"tag":"盘前","latestPrice":92.55,"preClose":92.45,"latestTime":"09:28 EST","volume":613,"amount":56569.797759999994,"timestamp":1766759332731},"postHourTrading":{"tag":"盘后","latestPrice":92.9,"preClose":92.9,"latestTime":"17:19 EST","volume":67047,"amount":6228610.65099,"timestamp":1766787557755},"volumeRatio":0.338721,"optionData":{"bulkOrders":[{"symbol":"AZN","call":false,"expireDate":1789704000000,"strike":"82.5","timestamp":1766767241669,"price":3.66,"volume":2000,"amount":732000,"type":"-"},{"symbol":"AZN","call":false,"expireDate":1776398400000,"strike":"85.0","timestamp":1766767241669,"price":2.36,"volume":2000,"amount":472000,"type":"+"}]},"impliedVol":0.2423,"impliedVolPercentile":0.176},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2594225778","title":"和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594225778","media":"药财社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594225778?lang=zh_cn&edition=full","pubTime":"2025-12-25 19:01","pubTimestamp":1766660515,"startTime":"0","endTime":"0","summary":"据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物。2Agios首创疗法再获FDA批准Agios Pharmaceuticals近日宣布，美国FDA已批准口服丙酮酸激酶激活剂Aqvesme用于治疗α型或β型地中海贫血成年患者。根据新闻稿，mitapivat为首款同时获FDA批准用于治疗非输血依赖型和输血依赖型α或β地中海贫血的药物。3阿斯利康自免“迷你双抗”在华申报上市12月24日，CDE网站显示，阿斯利康的戈鲁利单抗在华申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU2456880835.USD","LU0320765992.SGD","LU2236285917.USD","BK4585","LU0889565916.HKD","AZN","BK4568","LU1829250122.USD","LU2462157665.USD","LU2417539215.USD","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2594257739","title":"阿斯利康罕见病新药万诺维获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2594257739","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594257739?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:19","pubTimestamp":1766654340,"startTime":"0","endTime":"0","summary":"12月25日，界面新闻从阿斯利康处获悉，其与Ionis公司联合开发的万诺维®（英文商品名：Wainua®，通用名：依普隆特生钠注射液）在中国正式获批，该药物用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病（ATTRv-PN）患者。作为中国首个且目前唯一获批用于ATTRv-PN治疗的基因沉默剂，万诺维®的获批为ATTRv-PN患者提供了新的治疗选择，填补了国内在这一领域的治疗空白，有望显著改善患者生活质量，对推动国内罕见病治疗发展具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225173529a6ce0eb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225173529a6ce0eb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2462157665.USD","BK4585","LU2417539215.USD","AZN","LU1829250122.USD","LU0109394709.USD","BK4007","LU0889565916.HKD","LU2236285917.USD","BK4568","LU0320765992.SGD","LU2456880835.USD"],"gpt_icon":0},{"id":"2594572762","title":"超 70 亿美元引进！阿斯利康小核酸疗法国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594572762","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594572762?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:44","pubTimestamp":1766652263,"startTime":"0","endTime":"0","summary":"12 月 25 日，NMPA 官网显示，阿斯利康的 Eplontersen注射液在国内获批上市。此前，Eplontersen已于 2023 年 12 月获美国 FDA 批准上市，用于治疗成人遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病。2025 年 3 月，该药在欧盟获批同适应症。2023 年 7 月，双方再次扩大合作，阿斯利康又获得了在拉丁美洲商业化 Eplontersen 的独家权利，此项合作总金额也超过 36 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172611a6ce05d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172611a6ce05d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4568","LU2236285917.USD","AZN","LU0109394709.USD","LU1829250122.USD","LU0889565916.HKD","LU2417539215.USD","BK4585","LU2456880835.USD","BK4588","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2594233412","title":"阿斯利康与第一三共ADC抗癌药在华获批第五项适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233412","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233412?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:43","pubTimestamp":1766652224,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4080","BK4007","LU0320765992.SGD","BK4568","LU2417539215.USD","BK4588","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","LU1829250122.USD","ADC","LU2462157665.USD","BK4231","BK4585","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2594025721","title":"阿斯利康“戈鲁利单抗”国内申报上市，自免双抗新药剑指全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2594025721","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594025721?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:33","pubTimestamp":1766644399,"startTime":"0","endTime":"0","summary":"12月24日，据CDE网站显示，阿斯利康的戈鲁利单抗在国内申报上市。根据临床试验进展，推测此次申报的适应症为全身型重症肌无力。全身型重症肌无力是一种罕见、慢性且严重影响生活的自身免疫性神经肌肉疾病，其特征是进行性肌力下降与虚弱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225143342a6cd5c28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225143342a6cd5c28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0320765992.SGD","BK4007","LU2462157665.USD","BK4585","LU2236285917.USD","LU1829250122.USD","BK4568","LU0889565916.HKD","AZN","LU2456880835.USD","LU2417539215.USD","BK4588"],"gpt_icon":0},{"id":"2593479219","title":"加科思与阿斯利康合作开发KRAS抑制剂 交易总额突破20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593479219","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593479219?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:10","pubTimestamp":1766574606,"startTime":"0","endTime":"0","summary":"本报讯（记者张敏）近日，港股上市公司加科思药业集团有限公司（以下简称“加科思”）发布的公告显示，非全资附属公司北京加科思新药研发有限公司（以下简称“北京加科思”）与AstraZenecaAB（以下简称“阿斯利康”）订立许可与合作协议（以下简称“许可及合作协议”），就开发及商业化泛KRAS抑制剂JAB-23E73展开合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600872266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK4568","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK4007","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2593421806","title":"阿斯利康(AZN.US)自免双抗“戈鲁利单抗”在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593421806","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593421806?lang=zh_cn&edition=full","pubTime":"2025-12-24 13:52","pubTimestamp":1766555567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月24日，CDE网站显示，阿斯利康的戈鲁利单抗在华申报上市。根据临床试验进展，推测此次申报的适应症为全身型重症肌无力。戈鲁利单抗是一种迷你双抗，只包含了靶向C5的抗体重链可变区和与白蛋白特异性结合的抗体片段。全身型重症肌无力是一种罕见、使人衰弱、慢性的自身免疫性神经肌肉疾病，会导致肌肉功能丧失和严重无力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康(AZN.US)自免双抗“戈鲁利单抗”在华申报上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","BK4007","BK4568","LU2462157665.USD","BK4585","BK4588","LU2417539215.USD","AZN","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2593428103","title":"港股异动 | 加科思-B(01167)涨近5% 公司获阿斯利康近20亿美元BD大单 公司称首付比例均值偏上","url":"https://stock-news.laohu8.com/highlight/detail?id=2593428103","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593428103?lang=zh_cn&edition=full","pubTime":"2025-12-24 10:48","pubTimestamp":1766544525,"startTime":"0","endTime":"0","summary":"加科思将获得1亿美元的首付款，根据开发及商业化进度，还可获得最高19.15亿美元的里程碑付款，以及中国以外市场的净销售额特许权使用费。首付款占总金额比例为5%。在12月22日加科思召开的媒体沟通会上，加科思董事长兼首席执行官王印祥回应称，加科思此次BD交易是中国近几年来处于临床阶段的小分子抗肿瘤药中金额最大的对外授权。王印祥在沟通会上回应了首付款是否低于预期这一问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0320765992.SGD","BK4588","BK4007","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","01167","LU2236285917.USD","BK4585","BK4568","LU2417539215.USD","LU1829250122.USD","LU2462157665.USD","AZN","BK1574"],"gpt_icon":0},{"id":"2593433677","title":"阿斯利康肺癌试验药物组合未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433677","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593433677?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:12","pubTimestamp":1766412720,"startTime":"0","endTime":"0","summary":"阿斯利康表示，其试验性药物ceralasertib与已获批的癌症治疗药物Imfinzi的组合，在一项针对晚期肺癌的后期临床试验中未能达到主要目标。　　这家英国制药公司周一表示，研究结果显示，与局部晚期或转移性非小细胞肺癌患者的标准疗法相比，ceralasertib组合未能达到总体生存率这一主要目标。　　阿斯利康表示，ceralasertib和Imfinzi的组合总体上耐受性良好，没有出现新的安全性担忧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-22/doc-inhcsvvf6086289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","LU2236285917.USD","LU0109394709.USD","AZN","BK4007","BK4588","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","LU2417539215.USD","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2593448816","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448816","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593448816?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:55","pubTimestamp":1766393727,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家开发和商业化权利。在中国市场，加科思将与阿斯利康共同开发和商业化该产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598339468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","LU1829250122.USD","AZN","BK4007","BK4568","LU2236285917.USD","BK4585","LU0109394709.USD","LU2462157665.USD","LU0889565916.HKD","BK4588","LU2417539215.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2593171901","title":"阿斯利康入局，Pan-KRAS抑制剂技术路线之争开始逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593171901?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:45","pubTimestamp":1766364328,"startTime":"0","endTime":"0","summary":"当阿斯利康以20亿美元接手加科思 Pan-KRAS抑制剂项目的全球开发后，这场竞赛的本质已经发生变化。更重要的是，对阿斯利康来说，一个安全性更好的分子，更有可能在未来KRAS抑制剂联合治疗版图中占据优势。对阿斯利康来说，Pan-KRAS 的终极目标并不仅仅是在某个小人群中证明“能用”，而是成为联用时代的底座。相比之下，加科思 Pan-KRAS抑制剂 采用的是更为传统、成熟的小分子路线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","LU0109394709.USD","BK4007","LU0320765992.SGD","LU0889565916.HKD","01167","LU2456880835.USD","BK4588","BK4568","LU1829250122.USD","BK4585","LU2417539215.USD","AZN","LU2236285917.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2593124204","title":"加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2593124204","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593124204?lang=zh_cn&edition=full","pubTime":"2025-12-21 19:58","pubTimestamp":1766318290,"startTime":"0","endTime":"0","summary":"加科思-B(01167)公布，该集团的非全资附属公司北京加科思新药研发有限公司与AstraZeneca \nAB(阿斯利康)已订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2417539215.USD","LU0109394709.USD","BK4007","AZN","01167","LU2236285917.USD","BK4568","BK4588","LU2456880835.USD","LU0320765992.SGD","BK1161","BK4585","BK1574","LU0889565916.HKD","LU2462157665.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1057294990.SGD","LU1069347547.HKD","IE00BN8TJ469.HKD","LU1066053197.SGD","BK4007","LU1868836914.USD","LU1989772923.USD","LU0321505868.SGD","IE00BLSP4239.USD","BMY","LU1699723380.USD","LU0456855351.SGD","LU1066051498.USD","LU0106261372.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU1066051811.HKD","IE00BBT3K403.USD","SG9999002224.SGD","BK4559","NVS","LU1868836757.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0265550946.USD","LU1868836591.USD","LU1201861249.SGD","SG9999014567.USD","LU2133065610.SGD","LU0965508806.USD","LU1718418525.SGD","ROG","LU2324357040.USD","BK4516","LU1093756325.SGD","LU1116320737.USD","LU1116320901.HKD","LU1974910355.USD","AZN","LU0320765646.SGD","LU0985320562.USD","LU1162221912.USD","LU2125154778.USD","SG9999015358.SGD","BK4588","LU1037948541.HKD","LU2023250843.SGD","BK4532","AMGN","IE00BJT1NW94.SGD","LU0203347892.USD","LU1929549753.HKD","LU1670710588.SGD","LU1941712348.USD","04332","LU0006306889.USD","LU1934455194.USD","LU0238689110.USD","LU0306807586.USD","SG9999002232.USD","LU0868494617.USD","LU1571399168.USD","LU0211331839.USD","LU1585245621.USD","BK4533","LU0965509101.SGD","LU0265550359.USD","LU1941712264.USD","LU0225771236.USD","LU1032466523.USD","LU2361044865.SGD","SG9999015341.SGD","IE00B1BXHZ80.USD","LU0965509283.SGD","IE00BSNM7G36.USD","LU2023250504.SGD","LU0477156953.USD","LU2361045086.USD","LU0882574055.USD","LU1670711040.USD","LU1983299246.USD","LU2089984988.USD","SG9999013999.USD","LU0114720955.EUR","LU1868837300.USD","LU0861579265.USD","GILD","IE0009355771.USD","LU2360032135.SGD","SGXZ57979304.SGD","LU2361044949.HKD","LU1035773651.USD","LU0965509010.AUD","LU0648001328.SGD","JNJ","REGN","SG9999001440.SGD","LU1066051225.USD","LU0061475181.USD","LU1037948897.HKD","LU0130102774.USD","IE000M9KFDE8.USD","SG9999014559.SGD","IE00B4R5TH58.HKD","LU0130517989.USD","LU0306806265.USD","LU1323610961.USD","SG9999014542.SGD","LU2242646821.SGD","BK4581","LU1934455863.HKD","LU0237698245.USD","LU0070302665.USD","BK4534","GSK","IE00BLSP4452.SGD","SG9999001176.SGD","LU1670711123.USD","LU2468319806.SGD","LU0267386448.USD","LU2242652126.USD","LU1934455277.USD","LU0234572021.USD","LU1023059063.AUD","IE00BFXG1179.USD","LU1093756168.USD","LU0289739699.SGD","LU0980610538.SGD","LU1670710661.SGD","LU1989772840.SGD","LU0321505439.SGD","LU0098860793.USD","LU0203345920.USD","IE0002141913.USD","LU0320765489.SGD","LU2125154935.USD","SNY","LU0122379950.USD","LU1291159041.SGD","LU2106854487.HKD","MRK","SG9999001176.USD","LU0266013472.USD","BK4550","LU1917777945.USD","IE00B2B36J28.USD","LU0208291251.USD","LU1261432733.SGD","BK4585","LU0985481810.HKD","ABBV","LU1074936037.SGD","LU1868837136.USD","LU1989771016.USD","SG9999014575.USD","LU0225284248.USD","LU2461242641.AUD","LU0058720904.USD","LU1430594728.SGD"],"gpt_icon":1},{"id":"2592199939","title":"阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199939","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199939?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:03","pubTimestamp":1766138580,"startTime":"0","endTime":"0","summary":"本次试验目的是评估不适合或拒绝化疗的EGFRm阳性III期不可切除NSCLC患者在放疗前使用奥希替尼作为诱导治疗及在放疗后继续使用奥希替尼直至疾病进展的有效性。甲磺酸奥希替尼片为化学药物，适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4588","BK4134","BK4007","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","LU2236285917.USD","III","BK4585","BK4568","LU2417539215.USD","LU1829250122.USD","LU2462157665.USD","AZN"],"gpt_icon":0},{"id":"2592954199","title":"荷声科技完成Pre-A轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2592954199","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592954199?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:07","pubTimestamp":1766128034,"startTime":"0","endTime":"0","summary":"阿斯利康中金医疗产业基金近日宣布完成对杭州荷声科技有限公司Pre-A轮融资。中金资本董事总经理沈圆江表示：“荷声科技自成立以来，专注于突破高端超声核心技术，展现出显著成长潜力，同时在新一代超声系统发展趋势中具备前瞻性布局。本轮Pre-A融资完成，是对其技术实力和行业前景的积极认可。我们相信，在产业资源的协同下，荷声科技将稳步推进产品落地与规模化应用，持续引领中国高端医疗超声创新发展。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152604a6b5f722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152604a6b5f722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4588","BK4568","BK4585","LU2417539215.USD","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","AZN","LU1829250122.USD","LU2462157665.USD","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2591359889","title":"美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2591359889","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591359889?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:45","pubTimestamp":1765899900,"startTime":"0","endTime":"0","summary":"FDA批准阿斯利康（AZN）与第一三共（Daiichi Sankyo，TYO：4568）的fam-trastuzumab deruxtecan（Enhertu）联合帕妥珠单抗（pertuzumab）用于一线治疗，因DESTINY-Breast09试验显示其中位无进展生存期（PFS）达40.7个月，优于标准THP方案的26.9个月；帕妥珠单抗由罗氏（SWX：ROG）销售。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-16/doc-inhaziff7927164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LU2236285917.USD","BK4211","LU2462157665.USD","BK4585","PFS","BK4007","LU2456880835.USD","BK4195","LU1829250122.USD","LU2417539215.USD","LU0109394709.USD","LU0320765992.SGD","BK4568","AZN","LU0889565916.HKD"],"gpt_icon":0},{"id":"2591661576","title":"持续深耕血液肿瘤领域 阿斯利康旗下BTK抑制剂片剂纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661576","media":"广州日报新花城","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591661576?lang=zh_cn&edition=full","pubTime":"2025-12-15 01:14","pubTimestamp":1765732464,"startTime":"0","endTime":"0","summary":"政策加持、市场需要之下，药企正在不断突破以提升创新药的可及性。12月7日，在国家医保局公布的2025年医保目录中，阿斯利康旗下BTK抑制剂的升级剂型（片剂）被正式纳入医保，标志着阿斯利康在血液肿瘤领域发展迈入新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591031847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2236285917.USD","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","LU0320765992.SGD","BK4568","AZN","BK4585","BK4007","LU0109394709.USD","LU2456880835.USD","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2590538907","title":"医保覆盖、创新迭代、本土深耕：阿斯利康血液肿瘤按下“加速键”","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538907?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:43","pubTimestamp":1765374221,"startTime":"0","endTime":"0","summary":"血液肿瘤是最常见的恶性肿瘤之一，近年来发病率持续走高。世界卫生组织（WHO）数据显示，全球血液肿瘤新发患者数量由2015年的113.3万增长至2021年的130.5万，预计2030年增长至154.6万；中国新发患者同步增长，预计2030年增长至30万。庞大的患者基数下，跨国药企与本土创新药企纷纷加速布局，推动血液肿瘤在精准诊断、预后分层及靶向治疗等方面取得快速进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587919519.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587919519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","LU2417539215.USD","AZN","LU1829250122.USD","LU2462157665.USD","LU0109394709.USD","BK4568","LU0889565916.HKD","LU2456880835.USD","LU0320765992.SGD","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2590372841","title":"TD Cowen上调阿斯利康目标价至105美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372841","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590372841?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:23","pubTimestamp":1765337030,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","LU0889565916.HKD","LU2236285917.USD","LU2462157665.USD","BK4588","LU2456880835.USD","AZN","LU2417539215.USD","LU0320765992.SGD","BK4585","TD","LU0109394709.USD","BK4566","LU1829250122.USD","BK4207","BK4007"],"gpt_icon":0},{"id":"1153946041","title":"独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1153946041","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153946041?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:01","pubTimestamp":1765278094,"startTime":"0","endTime":"0","summary":"独家报道：美国FDA官员通知默沙东、赛诺菲安万特和阿斯利康的RSV抗体疗法将接受新的安全审查","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0823399737.USD","LU1066051225.USD","LU0058720904.USD","LU1037948897.HKD","LU2461242641.AUD","LU1301847155.USD","LU0792757196.USD","LU0006306889.USD","AZN","LU0949170426.SGD","LU1019634622.SGD","LU0211331839.USD","LU0432979614.USD","LU1267930227.SGD","LU2108987350.USD","LU0889565080.SGD","IE00BKPKM643.USD","LU0496365809.HKD","MRK","LU0211327993.USD","LU0265550359.USD","LU1430594728.SGD","LU0029864427.USD","LU0757432116.USD","LU2089984988.USD","LU0823416689.USD","LU1035773651.USD","BK4550","LU0106261372.USD","SG9999001176.SGD","SG9999002232.USD","LU2279689827.SGD","LU0557290698.USD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","LU0128525929.USD","BK4585","IE00BSNM7G36.USD","LU0203347892.USD","LU0526926950.USD","LU0499090636.EUR","LU0960981461.USD","LU0963555726.SGD","BK4534","IE00B4R5TH58.HKD","LU2361044865.SGD","LU0965509283.SGD","LU1496350171.SGD","LU2293690082.USD","IE00BLSP4452.SGD","LU0208291251.USD","LU1929549753.HKD","LU0997586432.USD","LU2023250504.SGD","LU0985320562.USD","LU1153585028.USD","LU2133065610.SGD","LU1983299246.USD","IE00BLSP4239.USD","LU0345777147.USD","LU0310799852.SGD","LU1934455194.USD","LU0784383803.USD","SG9999015341.SGD","LU0972486137.USD","LU1814569148.SGD","LU1051770623.HKD","SNY","LU1104425308.USD","LU2114397693.USD","LU0098860793.USD","IE0034235188.USD","LU1934455863.HKD","LU1261432733.SGD","LU0265550946.USD","LU1015430645.USD","LU0738911758.USD","LU1989771016.USD","LU2023251221.USD","LU0052756011.USD","LU0553294199.USD","LU0114720955.EUR","LU1023059063.AUD","LU1061106388.HKD","LU0238689110.USD","LU1093756325.SGD","LU1069347547.HKD","LU1934455277.USD","LU2023250843.SGD","SG9999015358.SGD","LU0266013472.USD","LU1481600234.SGD","IE00BN8TJ469.HKD","SG9999014567.USD","LU2539964713.USD","LU1066051498.USD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU0784384876.USD","LU1116320901.HKD","LU0158827948.USD","LU1093756168.USD","LU1291159041.SGD","BK4588","LU1162221912.USD","LU1880407132.USD","LU1487256676.USD","LU1941712348.USD","SG9999014542.SGD","LU0345777659.USD","03165","LU1084165304.USD","LU0661504455.SGD","LU0211326755.USD","LU0708994859.HKD","LU1037948541.HKD","LU0171293334.USD","LU1989772923.USD","LU1119994496.HKD","IE000M9KFDE8.USD","LU1066053197.SGD","LU1003077747.HKD","LU0784385170.HKD","LU1267930573.SGD","LU0882574055.USD","LU0122379950.USD","LU1003076772.USD","LU1585245621.USD","IE00B2B36J28.USD","LU2112291526.USD","LU0047473722.EUR","LU0128525689.USD","LU0949170772.SGD","LU1116320737.USD","LU1066051811.HKD","LU1064927863.SGD","LU2125154778.USD","LU2125154935.USD","LU2089283258.USD","LU1267930490.SGD","LU1267930813.SGD","LU1078025761.USD","LU1880407215.USD","LU0965509101.SGD","LU1153584641.USD","LU0070302665.USD","LU0289739699.SGD","LU0320765646.SGD","SG9999014575.USD","LU2468319806.SGD","LU1019632923.USD","LU0011850046.USD","LU1323610961.USD","SG9999001440.SGD","LU2089284900.SGD","SG9999001176.USD","LU1496350502.SGD","LU2361045086.USD","BK5011","LU0976567544.SGD","IE00BFTCPJ56.SGD","LU0575583348.USD","LU2360032135.SGD","LU2361044949.HKD","IE0002141913.USD","SGXZ57979304.SGD","LU0320765489.SGD","LU0965508806.USD","LU1699723380.USD","LU1571399168.USD","LU0545039389.USD","LU0310800965.SGD","LU1989772840.SGD","LU2293690249.USD","LU0211326839.USD","LU1974910355.USD","LU1941712264.USD","SG9999014559.SGD","LU2106854487.HKD","BK4533","BK4516","BK4007","LU0211328371.USD","LU1481599808.USD","SG9999013999.USD","BK4559","SG9999002224.SGD","LU0203345920.USD","LU0969580561.USD","LU0077335932.USD","LU0965509010.AUD","LU0957799991.USD","LU0640478417.SGD","LU0047473722.SGD","LU0964806797.USD","IE0009355771.USD","LU1057294990.SGD","LU0889566641.SGD","LU2091194634.USD","LU1917777945.USD","LU0861579265.USD","LU0310800379.SGD","LU0784385840.USD","IE00B3T34201.USD","LU2324357040.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.2573},{"period":"6month","weight":0.3236},{"period":"1year","weight":0.3944},{"period":"ytd","weight":0.411}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007634}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}